Asymptomatic MGD more common than symptomatic

Article

A symptom-based approach may lead to an underestimation of MGD prevalence

"The high proportion of asymptomatic patients should alert us to the possibility of unnoticed progression of meibomian gland dysfunction (MGD)," emphasized Dr Eloy Viso (Servico de Oftalmología, Complexo Hospitalario de Pontevedra, Pontevedra, Spain) when discussing the results of a recent study on a general Spanish adult population.

The study

A population-based approach was used to obtain a representative sample of the population noted Dr Viso. The possibility of selection bias was also evaluated to ensure the results were fair. "We used a stratified sampling procedure so a representative sample could be obtained in each age group and we performed a design based analysis to account for the stratified sampling and the unequal probability selection," added Dr Viso. "With respect to diagnostic criteria, which are an important cause of variability between studies, we included signs of the 2 categories described in the new MGD classification to reduce the number of false negatives and removed indirect indicators to reduce the number of false positives."

Additionally, a standardized symptoms questionnaire was employed. "We used the questionnaire developed by Schein et al.1 because it was the most widely used in population-based studies and because it included symptoms such as eyes stuck shut that have been considered, in spite of a lack of sufficient evidence, more characteristic of MGD," he continued. "The biomicroscopic examination of the ocular surface, however, was performed without knowledge of the results of the questionnaire."

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.